Kentucky's Revised Nursing Guidance on Cosmetic Procedures and IV Hydration: Where State Scope Rules Meet Federal Criminal Risk

Kentucky's Board of Nursing just rewrote the rules on what nurses can and cannot do in cosmetic, dermatological, and IV hydration practice. Most aesthetic operators will read it as a scope-of-practice memo and file it away. That is a mistake.

Buried in the same guidance are the exact pressure points federal prosecutors press in med spa and IV cases: who actually performed the procedure, whether a qualified provider ordered it, and what went into the bag. State boards police those questions with license discipline. The federal government polices them with fraud, kickback, and drug statutes that carry prison time.

A state board guidance document maps the scope rules. Federal prosecutors use the same map to identify where billing, delegation, and sourcing decisions crossed into criminal territory.

Key Takeaways

• Kentucky's revised Advisory Opinion Statement 35 ties nurse-performed aesthetic services to provider orders, supervision, and documented competency, and addresses IV hydration additives directly.
• When IV additives are compounded or sourced improperly, exposure can run under the Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 331 and 333.
• Billing aesthetic or IV services to a federal program without proper licensure or supervision can trigger healthcare fraud under 18 U.S.C. § 1347, up to 10 years per count.
• Compounding outside 21 U.S.C. §§ 353a and 353b requirements is a recurring federal theme in IV and peptide enforcement.
• Cash-pay models reduce billing fraud exposure but do not remove drug, kickback, or wire fraud exposure.
• Florida operators should treat out-of-state board updates as early warning. The Southern District of Florida applies the same theories to the dense cluster of med spa and IV businesses across South Florida.

What the Kentucky Guidance Actually Says

In June 2026, the Kentucky Board of Nursing revised Advisory Opinion Statement 35 on the roles of nurses in cosmetic and dermatological procedures. The revision sorts procedures into three levels, from microdermabrasion and light peels up through neuromodulators, dermal fillers, laser procedures, and IV hydration.

It states that LPNs and RNs may perform certain procedures when competent and properly supervised, but may not independently practice, order products, prescribe, or perform medical aesthetic procedures such as Botox or fillers outside the nursing scope. On IV hydration, the guidance is blunt. Mobile and freestanding IV clinics are not separately regulated in Kentucky, but IV fluid administration requires an order from a qualified healthcare provider. The guidance also addresses standing orders, additives, documentation, and immediate-use compounded sterile products.

Read as a compliance document, it is a roadmap of where aesthetic and IV practices go wrong.

The Kentucky guidance raises the same three questions federal agencies ask: who performed the service, did a qualified provider order it, and where did the IV additive come from.

What the Government Is Actually Building

Federal agencies have spent the last several years building med spa, IV, and peptide cases around three questions. First, who performed the service, and were they licensed and supervised to do it. Second, did a qualified provider actually evaluate the patient and order the treatment, or was the order a rubber stamp on a menu the patient picked. Third, where did the injectable or the IV additive come from, and was it an approved, properly compounded product.

Those are the same three questions the Kentucky guidance raises. The difference is the consequence. A board asks them to decide whether to discipline a license. The Department of Justice and the FDA ask them to decide whether to indict.

HHS-OIG and FDA agents coordinate IV and aesthetic practice cases across state lines. Out-of-state board guidance previews the enforcement priorities they bring to South Florida.

The Federal Statutes Behind the Scope Rules

When IV additives, peptides, or injectables are compounded outside the conditions of 21 U.S.C. § 353a, which governs traditional pharmacy compounding, or 21 U.S.C. § 353b, which governs outsourcing facilities, the products can be treated as unapproved or misbranded drugs. Distributing or administering misbranded or unapproved drugs is prohibited under 21 U.S.C. § 331, and 21 U.S.C. § 333 sets the penalties, which become felonies when the conduct is done with intent to defraud or mislead.

Billing is the other half. If aesthetic or IV services are submitted to a federal program and the claim misrepresents who performed the service or whether it was properly ordered and supervised, that is healthcare fraud under 18 U.S.C. § 1347, up to 10 years per count, with conspiracy under 18 U.S.C. § 1349 carrying the same exposure. Where remuneration moves between a clinic and a referral source or a supplier, the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b, comes into play, with False Claims Act civil exposure under 31 U.S.C. § 3729 running alongside.

Mistakes Aesthetic and IV Operators Make Early

The Kentucky guidance is, in effect, a list of the errors that draw scrutiny. The same errors draw federal scrutiny when the dollars and the products line up.

Letting unlicensed or under-supervised staff perform Level III procedures like injectables, laser, or IV hydration. The guidance sorts procedures by who may perform them. Federal prosecutors sort claims by whether the representation of proper performance was true.

Running IV menus where patients self-select without an individualized provider assessment and order. A rubber-stamp standing order is not an individualized order. Agents and prosecutors know the difference.

Using additives or compounded products without verifying the source, the approval status, and pharmacy compliance. Source verification and pharmacy compliance are not paperwork. They are the difference between a compliant practice and a federal drug case.

Treating standing orders as a substitute for a real, documented treatment plan. The Kentucky board said this directly. So do federal charging documents in IV cases.

Assuming a cash-pay model removes federal risk. It reduces billing exposure, not drug, kickback, or wire fraud exposure.

A federal defense table prepared for an IV and aesthetic practice case. Drug charges, healthcare fraud, and kickback statutes can all flow from the same conduct the Kentucky board described.

Strategic Defense and Why Timing Controls the Outcome

The defensible version of an aesthetic or IV practice and the indictable version often share the same services. What separates them is documentation, supervision, and sourcing, and the ability to show it.

A federal criminal defense attorney engaged early can audit those records before the government does, respond to a grand jury subpoena without handing the prosecution its own case, and answer a target letter with context rather than silence. That work has to happen before charges. Once an indictment is filed, the practice owner is negotiating a plea, not shaping a charging decision.

Florida operators should pay particular attention. Out-of-state board updates like Kentucky's are a preview, and the Southern District of Florida applies the same theories to the dense cluster of med spa and IV businesses across South Florida.

Common Questions

Running an Aesthetic or IV Practice and Seeing Federal Warning Signs?

If you have received a target letter or grand jury subpoena, or if federal agents have contacted your clinic, staff, or supplier, the first moves shape everything that follows. AMC Defense Law represents nurses, advanced practice providers, physicians, and med spa and IV operators in federal investigations and prosecutions, in Florida and nationwide. All consultations are confidential.

Aaron M. Cohen represents nurses, advanced practice providers, and aesthetic and IV practice operators in federal investigations in South Florida and nationwide.

This article is for informational purposes only and does not constitute legal advice. Reading this article does not create an attorney-client relationship. If you are under investigation or believe you may be a target of a federal or state health care investigation, consult a qualified federal criminal defense attorney immediately.